;

Exciting news from Teva api at this year’s CPhI Japan

Exciting news from teva api at this year’s CPhI Japan

Gil Feldman, President of Teva api Japan

 

It is almost a year since last year’s CPhI in Japan. This year, teva api will be attending right at the front of the exhibition center at booth P-10 in East Hall 1,2,3 from April the 18th until closing time on April 20th.  

Events CPhI Products

CPhI Japan is without doubt a great way to meet partners and colleagues and to form new networks as over 20,000 pharma professionals will be attending the three-day exhibition.

Gil Feldman, President of Teva api Japan:

Gil Feldman, President of TAPI Japan

Mr. Gil Feldman and all of teva api's local team and experts are looking forward to meeting you at the event – See you at booth P-10 in East Hall 1,2,3 

 

The entire teva api Japan team are really looking forward to seeing you in Tokyo, to renew acquaintances, or to meet you for the first time. If you would like to book a meeting with us, please contact us here or via one of our account managers. You are also welcome to just drop by our booth.

Our Special Guest This Year

We traditionally use CPhI to focus on the teva api pipeline for Japan and this year is no exception. Gil and his team will be supported by our senior director of R&D, Ernest Mestrovic, who will be introducing our exciting pipeline developments for the Japanese Market. Mr. Mestrovic will also be taking part in various discussions about new developments and R&D related topics for the Japanese market. His experience and knowledge mean that these discussions are not to be missed.

 

Teva api To Introduce New Pipeline Products:

Teva api will introduce pipeline products in the fields of: Oncology, Metabolic, Anti-coagulant, Respiratory and others.

 

Teva api is the leading international supplier of active pharmaceutical ingredients (APIs). With the industry’s broadest portfolio of more than 370 high quality API products, we serve nearly 1,000 customers in more than 100 countries. A stand-alone unit within Teva Pharmaceutical Industries, our history in the generic API industry dates back more than 80 years.

In Japan, we currently have 120 DMF’s and we add approximately five new products every year.

 

Mr. Gil Feldman and all of TAPI's local team and experts are looking forward to meeting you at the event – See you at booth P-10 in East Hall 1,2,3